Why JeanMarie Guenot’s Experience and Expertise is perfect for Amphivena Therapeutics


Over the years, JeanMarie Guenot has built an impressive professional career and she continues to impress by making a difference in the pharmaceutical and biotechnology industry. She is an accomplished scientist and business executive that everybody in the pharmaceutical world admires. Her remarkable records in the many organizations that she has worked for speaks a lot about her passion for success in each and everything that she does. She is instilled with extensive experience in the industry and some of her accomplishments include the discovery of several drugs, development of companies, as well as negotiating merger transactions for PDL’s R&D.






Growing up, JeanMarie Guenot was an active and diligent girl. Her hard work and determination secured her spot at the University of California where she studied physical chemistry, medicinal chemistry, protein structure prediction, quantum mechanical methods for molecular dynamics, drug design, as well as NMR refinement. She eventually earned herself a Ph.D. and went to the prestigious University of Pennsylvania’s Wharton School, where she received her MBA.



Career Background



JeanMarie Guenot has worked for a number of different public and private companies in the biotechnology, venture capital, pharmaceuticals as well as business development sectors. She started her career immediately after her Ph.D. degree in 1993 where she worked at the Hoffman-La Roche as a scientist in Preclinical R&D.



She first got into her business career at Atlas Venture. Being in charge of the venture capital investment management, Guenot helped in making life sciences companies successful. She has also worked with PDL BioPharma as the vice president as well as a managing partner. In 2009, she established the SKS Ocular LLC, which serves as a biopharmaceutical organization based in San Diego.



Amphivena Therapeutics



JeanMarie is currently the president of Amphivena Therapeutics. The company has its headquarters in San Francisco and specializes in developing immune therapies for the treatment of cancer. Founded in 2013, Amphivena Therapeutics has a goal to re-establish the flow of life by restoring the cellular balance. The company believes that if blood is actively forming, circulating, and functioning, then the immune system of the body will destroy any present tumors along with their precursors. With JeanMarie as the leader of this organization, the company is on the right track to achieve that goal.